ALK Strengthens Executive Leadership Team for Key Regions
ALK (ALKB:DC / OMX: ALK B) has made a strategic decision to include its critical commercial regions in the Executive Leadership Team (ELT) to enhance the execution of its Allergy+ strategy. The move aims to improve operational efficiencies and strategic direction within these vital markets.
New Leadership Roles Introduced
Starting from October 1, ALK will feature direct representation from its two key commercial areas, Europe and North America, within the ELT. Dr. Flora Beiche-Scholz, currently serving as the Senior Vice President for the European region, will be elevated to the position of Executive Vice President (EVP) and will oversee ALK’s commercial operations in Europe. Furthermore, a new EVP will be appointed for North America, joining the ELT in the near future. Until this new appointment is finalized, Søren Niegel, the current EVP, will continue to lead the North American operations, allowing for a seamless transition.
Dr. Flora Beiche-Scholz's Impact on Europe
Dr. Flora Beiche-Scholz has been with ALK since 2012. She initially served as General Manager for the German market, where she skillfully transformed its operations, resulting in substantial growth. Her leadership was pivotal as ALK Germany became the company’s largest market globally. In her role as Senior Vice President, she was responsible for managing ALK’s pan-European operations, showcasing her ability to deliver strong growth and commercial success across the region.
Søren Niegel's Tenure and Contributions
Søren Niegel has made significant contributions to ALK since his start in 2012. His expertise as the EVP of Commercial Operations has been instrumental in driving global sales and marketing initiatives. His leadership facilitated the introduction of SLIT-tablets, establishing them as a standard treatment for individuals suffering from severe respiratory allergies.
CEO Peter Halling's Vision
President and CEO Peter Halling expressed optimism regarding the enhancement of ALK's operational structure. He stated that the execution of the Allergy+ strategy is gaining traction with successful product launches and broader market penetration. He noted the importance of varied approaches in different regions, understanding that each area presents distinct challenges and opportunities.
Strategic Importance of Direct Representation
By including European and North American operations in the executive team, ALK aims to optimize its strategic initiatives and operational coordination across these markets. This direct representation will enable the company to respond more swiftly to market demands while fostering innovation in treatments.
The composition of the Executive Leadership Team will henceforth be as follows:
- Peter Halling, President & CEO
- Claus Steensen Sølje, EVP & CFO
- Henriette Mersebach, EVP, R&D
- Christian G. Houghton, EVP, Product Supply
- Flora Beiche-Scholz, EVP, Commercial Operations Europe
- Søren Niegel, EVP, Commercial Operations North America (Interim)
- Lika Thiesen, EVP, Global People & Organisation
- Jacob Glenting, SVP, Global Strategy & Corporate Development & Global Marketing
- Jan Engel, SVP, Global Quality
About ALK
ALK is a globally recognized pharmaceutical company dedicated to treating allergies and allergic asthma. The company specializes in allergy immunotherapy (AIT), treatments for acute anaphylaxis, along with various services for healthcare professionals and allergy sufferers. With its headquarters in Hørsholm, Denmark, ALK employs around 2,800 individuals worldwide and is listed on Nasdaq Copenhagen, making significant strides in the pharmaceutical landscape.
Contact Information
If you require further information, please reach out to:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
Frequently Asked Questions
What changes have been made to ALK's Executive Leadership Team?
ALK has included its key commercial regions, Europe and North America, in the Executive Leadership Team to enhance strategic execution.
Who is the new Executive Vice President for Europe?
Dr. Flora Beiche-Scholz has been appointed as the new EVP, leading ALK’s Commercial Operations in Europe.
What role will Søren Niegel play after these changes?
Søren Niegel will serve as the interim EVP for Commercial Operations in North America until a permanent successor is appointed.
How will these changes impact ALK's strategy?
This restructuring aims to strengthen ALK's operational coordination and responsiveness to market demands, particularly in key regions.
What is ALK's main focus as a company?
ALK specializes in allergy treatments and aims to provide innovative solutions for allergy and allergic asthma sufferers worldwide.
